Publications by authors named "E Grischke"

Claim this Profile
A
Atezolizumab Monotherapy Window Preceding Combined Neoadjuvant Chemotherapy and Immune Therapy in Triple-Negative Breast Cancer-The neoMono Trial.
Hans-Christian Kolberg, Johannes Schumacher, Ramona Erber, Michael Braun, Peter A Fasching, Eva-Maria Grischke

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trial.
Darren Korbie, Clare Stirzaker, Oleg Gluz, Christine Zu Eulenburg, Ulrike Nitz, Eva-Maria Grischke

Mol Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.
Gilda Schmidt, Oleg Gluz, Matthias Christgen, Mattea Reinisch, Sherko Kümmel, Eva-Maria Grischke

Breast Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Lisa Richters, Oleg Gluz, Nana Weber-Lassalle, Matthias Christgen, Heinz Haverkamp, Eva-Maria Grischke

JAMA Netw Open· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study.
Marcus Schmidt, Tobias Hesse, Oliver Hoffmann, Bernhard J Heinrich, Tjoung-Won Park-Simon, Eva-Maria Grischke

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis